obeldesivir in filovirus disease · n=0
Reason given: The study was withdrawn after the Marburg outbreak in Rwanda was declared over, prior to enrollment of any participants.
Obeldesivir in rsv infection · n=4
Reason given: Study was terminated by Sponsor; the decision was not due to any safety findings.
WONDERS2Phase 2/3 · started 2024 · terminated lepetegravir in hiv-1-infection · n=73
Reason given: Sponsor decision to terminate study.
Obeldesivir in rsv infection · n=150
Reason given: Study was terminated by Sponsor; the decision was not due to any safety findings.
Obeldesivir in covid-19 · n=3
Reason given: Study was terminated by Sponsor; the decision was not due to any safety findings.
COSMICPhase 2 · started 2023 · terminated Edecesertib in cutaneous lupus erythematosus (cle) · n=20
Reason given: Sponsor Decision
BIRCHPhase 3 · started 2022 · terminated Obeldesivir in covid-19 · n=468
Reason given: The study was stopped early as it was determined there would not be a statistically significant treatment effect associated with the primary endpoint due to the low number of events.
ZUMA-25Phase 2 · started 2022 · terminated Brexucabtagene Autoleucel in relapsed/refractory waldenstrom macroglobulinemia · n=19
Reason given: Sponsor decision to terminate study.
Magrolimab in metastatic colorectal cancer · n=77
Reason given: Sponsor decision to terminate study
Magrolimab in acute myeloid leukemia · n=378
Reason given: Study was terminated due to futility
GS-5718 in rheumatoid arthritis · n=0
Reason given: Sponsor decision to withdraw study.
Magrolimab in triple-negative breast cancer · n=92
Reason given: Sponsor decision to terminate study.
Magrolimab in multiple myeloma · n=36
Reason given: This study was terminated early due to the Sponsor's decision to discontinue development of the investigational drug and close the program.
Magrolimab in solid tumor · n=106
Reason given: Sponsor decision to terminate study
Magrolimab in head and neck squamous cell carcinoma · n=193
Reason given: Sponsor decision to terminate study
Magrolimab in acute myeloid leukemia · n=258
Reason given: Study discontinued due to futility.
Tirabrutinib in chronic spontaneous urticaria · n=0
Reason given: Development program terminated
Magrolimab in myeloid malignancies · n=54
Reason given: Sponsor decision to terminate the study.
REDPINEPhase 3 · started 2021 · terminated Remdesivir in covid-19 · n=249
Reason given: The study was terminated due to study enrollment feasibility. This decision is not based on efficacy or safety concerns.
Filgotinib in ankylosing spondylitis · n=0
Reason given: Development program terminated
Filgotinib in ankylosing spondylitis · n=0
Reason given: Development program terminated
RDV in covid-19 · n=584
Reason given: The study was terminated due to study enrollment feasibility and changing needs of non-hospitalized participants. This decision is not based on efficacy or safety concerns.
ENHANCEPhase 3 · started 2020 · terminated Magrolimab in myelodysplastic syndromes · n=539
Reason given: Study discontinued due to futility based on a planned analysis
FalconPhase 2 · started 2019 · terminated Tilpisertib in ulcerative colitis · n=19
Reason given: Sponsor terminated the study since a new molecular entity was able to achieve greater target coverage
Filgotinib in psoriatic arthritis · n=67
Reason given: Development program terminated
Filgotinib in psoriatic arthritis · n=106
Reason given: Development program terminated
Seladelpar in primary sclerosing cholangitis · n=1
Reason given: Study was terminated as a precautionary measure due to histological findings in a nonalcoholic steatohepatitis (NASH) study (CB8025-21730, NCT03551522).
PRIMISPhase 3 · started 2019 · terminated Cilofexor in primary sclerosing cholangitis · n=419
Reason given: Following recommendation of the external Data Monitoring Committee, after it reviewed the results of a planned interim futility analysis.
SOF/VEL/VOX in hepatitis c virus infection · n=21
Reason given: SOF/VEL/VOX will not be evaluated in younger age groups.
Seladelpar in nash - nonalcoholic steatohepatitis · n=181
Reason given: unexpected histological findings
GS-9131 in hiv-1-infection · n=21
Reason given: GS-9131 did not meet the targeted antiviral response
Inarigivir Soproxil in chronic hepatitis b · n=123
Reason given: Study was terminated due to sponsor's decision to not pursue further development of inarigivir soproxil in chronic hepatitis B.
ALPINE 2Phase 3 · started 2017 · terminated AZLI in pseudomonas aeruginosa respiratory tract infection/colonization · n=149
Reason given: Study was terminated early by sponsor due to the challenges and risks introduced by Coronavirus disease 2019 (COVID-19) pandemic.
HUMBOLDTPhase 2 · started 2017 · terminated Filgotinib in noninfectious uveitis · n=74
Reason given: Development program terminated
SEL in nonalcoholic steatohepatitis · n=808
Reason given: This study was terminated early due to lack of efficacy based on the results of the Week 48 analysis as prespecified in the clinical study protocol.
SEL in nonalcoholic steatohepatitis · n=883
Reason given: This study was terminated early due to lack of efficacy based on the results of the Week 48 analysis as prespecified in the clinical study protocol.
GS-5829 in advanced estrogen receptor positive her2- breast cancer · n=14
No reason recorded in the registry.
Andecaliximab in rheumatoid arthritis · n=15
Reason given: Study was terminated by sponsor and decision was not due to any safety signals.
Cilofexor in primary biliary cholangitis · n=71
Reason given: The study was terminated because of the availability of alternate therapies for primary biliary cholangitis (PBC).
Magrolimab in non hodgkin lymphoma · n=178
Reason given: Study terminated early due to the magrolimab program discontinuation.
Andecaliximab in cystic fibrosis · n=6
Reason given: Discontinuation of development for this indication
DISCOVERPhase 3 · started 2016 · terminated F/TAF in pre-exposure prophylaxis of hiv-1 infection · n=5399
Reason given: Following review of accumulated safety data from DISCOVER and real-world use of F/TAF, the sponsor determined that the long-term safety of F/TAF had been demonstrated and no further safety monitoring within the study was required.
IMMU-132 infusion is administered to participants in one arm for the study in triple-negative breast cancer · n=0
Reason given: FDA asked to administratively split from IND115621- to open a new IND you need to file a protocol we only drafted it to get the IND open - never initiated
ENTO in chronic graft versus host disease · n=66
No reason recorded in the registry.
Entospletinib in non-hodgkin lymphoma · n=10
No reason recorded in the registry.
Idelalisib in follicular lymphoma · n=96
Reason given: Gilead has made the decision to close the study due to enrollment challenges
Alobresib in metastatic castrate-resistant prostate cancer · n=31
No reason recorded in the registry.
LDV/SOF in hepatitis c virus infection · n=87
Reason given: Due to lack of feasibility of enrolling participants, the study was terminated early.
Placebo Comparator in primary biliary cirrhosis (pbc) · n=41
Reason given: Study stopped early after review of safety and efficacy demonstrated efficacy proof-of-concept and need for dose reduction.
Idelalisib in follicular lymphoma · n=10
No reason recorded in the registry.
Andecaliximab in ulcerative colitis · n=165
No reason recorded in the registry.
Entospletinib in acute myeloid leukemia · n=148
No reason recorded in the registry.
Entospletinib in acute lymphoblastic leukemia · n=30
No reason recorded in the registry.
GS-6615 in ischemic heart disease · n=0
Reason given: Anticipated recruitment challenges
Andecaliximab in crohn's disease · n=187
No reason recorded in the registry.
Idelalisib in chronic lymphocytic leukemia · n=57
No reason recorded in the registry.
Eleclazine in hypertrophic cardiomyopathy · n=172
No reason recorded in the registry.
Eleclazine in long qt syndrome type 3 · n=41
No reason recorded in the registry.
Idelalisib in b-cell chronic lymphocytic leukemia (cll) with 17p deletion · n=102
No reason recorded in the registry.
Idelalisib in chronic lymphocytic leukemia · n=311
No reason recorded in the registry.
IMMU-107 in metastatic pancreatic cancer · n=334
Reason given: The DSMB conducted an interim analysis on overall survival, which showed that the treatment arm did not demonstrate a sufficient improvement in OS vs. placebo.
IMMU 130 in metastatic colorectal cancer · n=0
Reason given: No participants enrolled
EVG in acquired immune deficiency syndrome (aids) · n=31
No reason recorded in the registry.
Entospletinib in chronic lymphocytic leukemia · n=66
Reason given: Study was terminated due to safety measures.
Entospletinib MM in chronic lymphocytic leukemia · n=326
Reason given: Sponsor's decision to discontinue development of entospletinib.
Labetuzumab Govitecan (LG) in metastatic colorectal cancer · n=92
No reason recorded in the registry.
RAINIERPhase 2 · started 2013 · terminated Simtuzumab in idiopathic pulmonary fibrosis · n=544
Reason given: The Study was terminated due to lack of efficacy.
YosemitePhase 3 · started 2013 · terminated Placebo in indolent non-hodgkin's lymphomas · n=295
No reason recorded in the registry.
Idelalisib in indolent non-hodgkin's lymphomas · n=475
No reason recorded in the registry.
Placebo in liver fibrosis due to nash · n=222
No reason recorded in the registry.
Idelalisib in chronic lymphocytic leukemia · n=261
No reason recorded in the registry.
NASHPhase 2 · started 2012 · terminated Placebo in liver fibrosis due to nash · n=259
No reason recorded in the registry.
ATLASPhase 2 · started 2012 · terminated Simtuzumab in idiopathic pulmonary fibrosis · n=34
Reason given: The Study was terminated due to lack of efficacy.
Idelalisib in chronic lymphocytic leukemia · n=161
No reason recorded in the registry.
hLL1-DOX (IMMU-115) in non-hodgkin's lymphoma · n=13
Reason given: Study was terminated due to lack of efficacy, as a result, the stability program for the drug product was discontinued
GS-1101 in chronic lymphocytic leukemia · n=0
No reason recorded in the registry.
Simtuzumab in colorectal cancer · n=266
No reason recorded in the registry.
GS-5885 in chronic hepatitis c · n=248
No reason recorded in the registry.
Idelalisib in chronic lymphocytic leukemia (cll) · n=105
No reason recorded in the registry.
hLL1-DOX (the doxorubicin conjugate of milatuzumab) in multiple myeloma · n=17
Reason given: Study was terminated due to lack of efficacy
Veltuzumab and 90Y-Epratuzumab Tetraxetan in non hodgkin's lymphoma · n=0
Reason given: No subjects enrolled
Idelalisib in chronic lymphocytic leukemia · n=202
No reason recorded in the registry.
CYT997 in glioblastoma multiforme · n=20
Reason given: Strategic
Ambrisentan in idiopathic pulmonary fibrosis · n=40
No reason recorded in the registry.
GS-9450 in hcv infection · n=307
Reason given: Reports of significant laboratory abnormalities and adverse events in a number of clinical study participants.
regadenoson in heart disease · n=22
Reason given: Slow enrollment
Cicletanine in pulmonary arterial hypertension · n=162
No reason recorded in the registry.
MBX-102 in type 2 diabetes mellitus · n=242
Reason given: MBX-102 did not meet the target efficacy profile of HbA1c change.
Ambrisentan in idiopathic pulmonary fibrosis · n=494
Reason given: Lack of efficacy
CYT997 in relapsed and refractory multiple myeloma · n=5
Reason given: Difficulty enrolling patients
veltuzumab in purpura, thrombocytopenic, idiopathic · n=48
No reason recorded in the registry.
GS-9219 in non-hodgkin's lymphoma · n=32
Reason given: Unacceptable safety profile
Darusentan in hypertension · n=661
Reason given: Study DAR-312 did not meet its primary co-endpoints.
Darusentan in hypertension · n=282
Reason given: Study DAR-312 did not meet primary co-endpoints
Epratuzumab (hLL2- anti-CD22 humanized antibody) in waldenstrom macroglobulinemia · n=31
Reason given: low accrual
Enoximone in heart failure, congestive · n=175
No reason recorded in the registry.
Enoximone in heart failure, congestive · n=1800
No reason recorded in the registry.